-
K1221 HRP Goat Anti-Mouse IgG Guide
2026-09-07
Explore how an Affinity-Purified Goat Anti-Mouse IgG (H+L), HRP Conjugated secondary antibody can strengthen mechanistic osteoarthritis studies. This guide connects assay architecture, signal amplification, and the wogonin–LSD1-p65 evidence framework to practical Western blot, ELISA, IHC, and ICC decisions.
-
Amikacin–Lysozyme Binding: Multimodal Evidence
2026-09-07
A 2024 study combined tritium probing, fluorescence spectroscopy, interfacial measurements, enzymatic assays, and molecular docking to compare amikacin and levofloxacin binding to lysozyme. The results separate preservation of protein secondary structure from preservation of catalytic function, showing that amikacin nearly eliminates lysozyme activity while levofloxacin leaves key catalytic residues largely unaffected.
-
Ciprofloxacin Hydrochloride: Mechanism & Research Use
2026-09-05
Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Evidence also supports model-specific immunomodulatory, apoptosis, and autophagy effects, while single-cell studies show that ciprofloxacin interactions with tetracycline depend on bacterial survival and growth state.
-
HA Tag Peptide: From Mechanism to Translation
2026-09-04
Mechanistic oncology studies increasingly depend on precise capture, detection, and release of engineered proteins. This thought-leadership article examines how the Influenza Hemagglutinin (HA) Peptide can support rigorous validation of the NEDD4L–PRMT5–AKT/mTOR axis while clarifying what the reagent can—and cannot—prove in translational research.
-
Erastin: Practical Ferroptosis Research Guide
2026-09-04
Erastin is a practical ferroptosis inducer for probing redox failure in RAS- or BRAF-relevant tumor models. This guide connects product handling with orthogonal viability, ROS, and lipid-peroxidation workflows, while showing how the GBM GPR68–ATF4 study can inspire—but not replace—direct Erastin validation.
-
CAPE, TcdB, and Microbiota in C. difficile Infection
2026-09-03
The reference study identifies caffeic acid phenethyl ester (CAPE) as a candidate inhibitor of the Clostridioides difficile toxin TcdB and connects toxin suppression with improved outcomes in a murine infection model. Its integrated toxin, animal, microbiome, and metabolomics data support an anti-virulence strategy, while the preclinical evidence still requires stronger validation of direct binding, efficacy, and translational relevance.
-
Omeprazole (A2845): Research Workflow Guide
2026-09-03
This guide explains how to prepare, store, and apply Omeprazole (SKU A2845) in gastric acid secretion research, proton pump inhibition assays, and related antiulcer activity studies. It is intended for controlled scientific workflows only and should not be used for diagnosis, treatment, or other medical purposes.
-
Cell lysis buffer for WB and IP in CAF Studies
2026-09-02
Cell lysis buffer for WB and IP supports non-denaturing protein extraction for Western blotting, immunoprecipitation, and co-immunoprecipitation. Its defined detergent-salt formulation and protease and phosphatase inhibitor cocktail help preserve protein abundance, phosphorylation status, and selected native interactions during sample preparation.
-
Rosiglitazone and the Next Era of Adipose Browning
2026-09-02
Rosiglitazone (Brl-49653) is more than a conventional PPARγ agonist: used with modern genetic and thermogenic models, it can help translational researchers distinguish adipogenesis, adipose browning, and insulin sensitivity modulation. New SETD7 findings provide a framework for testing how receptor activation interacts with endogenous thermogenic control.
-
FGFR–TGFβ/PI3K–AKT Control of Periostin
2026-09-01
Labrèche et al. identify a context-dependent signaling circuit in which FGFR activity, TGFβ, PKC, and PI3K/AKT jointly regulate periostin expression in Neu-positive breast cancer cells. The study links epithelial acquisition of periostin to dynamic pathway cross-talk rather than to a single constitutive oncogenic signal, providing a framework for interpreting tumor–stroma interactions in HER2-related disease.
-
Lanabecestat (AZD3293) Experimental Workflow
2026-09-01
Build a practical BACE1 workflow around Lanabecestat (AZD3293) to connect amyloid-beta reduction with neuronal function. This guide emphasizes partial inhibition, orthogonal readouts, assay controls, and troubleshooting rather than relying on biochemical potency alone.
-
Canagliflozin: A Mechanistic Assay Control
2026-08-31
Canagliflozin hemihydrate is more than an SGLT2 research reagent: it can help define assay boundaries in mTOR inhibitor discovery. This guide connects renal glucose reabsorption inhibition with drug-sensitized yeast methodology and practical experimental interpretation.
-
Lumiracoxib and the Timing of COX-2 Biology
2026-08-31
Lumiracoxib is more than a selective COX-2 inhibitor for reducing inflammatory signals: it is a time-resolved research tool for separating protective and reparative functions of cyclooxygenase-2. Evidence from a Bothrops asper venom-induced muscle injury model shows that early pathway inhibition can worsen ischemia, while later inhibition may enhance VEGF- and MMP-associated revascularization. This article translates those findings into assay strategy, translational guardrails, and a practical framework for using Lumiracoxib in inflammation, ischemia, and tissue-repair studies.
-
Bifendate, Autophagy, and Lipid Droplet Accumulation
2026-08-30
The reference study identifies bifendate as an autophagy inhibitor that acts at several lysosome-related steps rather than at a single checkpoint. Its attenuation of oleic acid-induced lipid droplet accumulation provides a mechanistic framework for studying how hepatoprotective compounds influence autophagy, lysosomal function, and lipid homeostasis.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-08-29
Hao et al. developed ICG-loaded metal–organic framework nanoparticles functionalized with the PD-1 inhibitory polypeptide AUNP12 through a glutathione-responsive disulfide linkage. The platform combines near-infrared photothermal ablation with localized immune-checkpoint blockade, providing a mechanistic response to the limited durability of single-modality photothermal therapy.